Technology Background

On May 25, 2025, Regen Healthcare Group Pte. Ltd. (“利晶医疗健康集团（私人）有限公司”, RS) entered into a strategic partnership with ZHONGKE ZHONGLUAN BIOTECHNOLOGY GROUP LIMITED (“中科中銮生物科技（广东）有限公司”, ZZ).

ZZ is a China-based National High-Tech Enterprise focused on regenerative medicine, biotechnology R&D, and technological innovation. Its core businesses span biopharmaceuticals, medical devices, and health management. The company holds multiple invention patents, including stem cell differentiation formulations, and was recognized in 2026 as a Specialized, Sophisticated, and Innovative SME by the Shenzhen municipal authorities.

Regen Healthcare Guangdong

As a wholly owned subsidiary and key operating entity of Regen Healthcare Group Pte. Ltd. (RS) in the Asia-Pacific region, Regen Healthcare Industry (Guangdong) Co., Ltd. (RHGD) serves as a core execution platform for the Group.

Leveraging the Group’s strategic partnerships and core technology licenses from leading biotechnology companies — including Zhongke Zhongluan (ZZ) —RHGD focuses on the biotechnology and broader healthcare sectors, delivering end-to-end solutions for mid- to large-scale enterprise (B2B) clients across the region. These solutions span technology assessment, industrial incubation, and full-scale commercial deployment.

Personnel Introduction

CHARLIE IN

Dr. Charlie In brings over 40 years of business experience, with the past two decades focused on China investments and private banking advisory, during which he has supported multiple Chinese enterprises in investment and public listing initiatives.

He has served as an advisor to leading multinational corporations including AXA, Citigroup, IBM, and Siemens, and has held Chairman roles on several ASX- and SGX-listed companies. Dr. In has also served as President of the Singapore Direct Selling Association and as an advisor to multiple institutions. He has taught MBA programs at the Singapore Institute of Management, the University of South Australia, and several top universities in China.

Dr. In is the author of Family Financial Freedom and From A to Z: Achieving Wealth and Financial Freedom, which received the Big Ben Golden Mulberry Award (2010) and China Best-Selling Book Honor (2017) respectively. His academic credentials include an MBA from the University of East Asia, Macau, a Diploma from the Chartered Institute of Marketing (UK), and postgraduate qualifications from Macquarie University.

In 2018, he co-founded Raffles Capital Limited, which was listed on the Canadian Securities Exchange in 2020. In 2021, he co-founded Raffles E-Money International (REMI), providing services in offshore banking, crypto payments, and tokenized financing solutions.

Founder of Raffles Capital

Shareholder of Regen Healthcare

Non Executive Director

CHNG HEE KOK

Mr. Chng has helmed numerous public companies that are listed on the Malaysia, Singapore and Hong Kong stock exchanges. He has led companies in chemical, paper making, metal fabrication, hospitality and property development, bottled drinks, shipping, commercial buildings and entertainment complexes. Although he has been a Member of Parliament in Singapore for 17 years, he is well versed with the capital markets, corporate finance and governance of public listed companies. He has served on government statutory boards such as Sentosa Development Corporation and Public Utilities Board. He is a fellow member and was a Director of Singapore Institute of Directors. His current interest is in green mobility energy ventures and the global talent and technology transformer programs.

Chairman, Independent Director

ANGELA YE

Ms. Angela has more than 23 years of financial management experience with 15 years of hands-on CFO responsibility serving one of Indonesia’s largest conglomerates. Angela is versed with Asian cross-border financing of investments and projects. She provides guidance and advisory in financial strategy, budgeting, risk management, credit control and fundraising. Her recent assignments advised several Asian companies to list on Nasdaq and NYSE. She is versed with the North American listing methods and professional preparations which adds significant value to the clients who are not apt with American communications and culture. Her key research now is in corporate finance and governance of emerging Asian companies.

Independent Director, Head of Audit

LI JING

Ms. Li Jing has over a decade of deep experience in regenerative medicine and medical aesthetics. Since 2013, she has been actively involved in the translation and commercialization pathways of novel regenerative medicine materials. Through systematic research into frontier technologies, she built a comprehensive translation framework, driving innovative clinical and commercial applications of regenerative materials. She also led team building and resource integration, laying a solid foundation for industrial-scale deployment.

In 2017, Ms. Li founded the “Ai Jiayuan” brand, spearheading the expansion of 128 stores nationwide and establishing a precision service ecosystem serving over 500,000 members. She successfully advanced the rollout of light medical aesthetics solutions and developed flagship store clusters in prime commercial districts in Shenzhen, creating a strong regional benchmark model.

In 2022, she further expanded into the regenerative medicine and wellness-lifestyle healthcare sectors by joining Zhongke Zhongluan Group. In the same year, she joined Regen Healthcare as a strategic investor, where she led the end-to-end development of regenerative medicine (high-end medical aesthetics) value chains, forming a closed-loop industry ecosystem. Concurrently, she became actively involved in philanthropic initiatives, serving as a Charity Ambassador for the Group’s “Healthy Steps, Moving Forward Together” public welfare program, contributing to broader social impact.

In 2025, in recognition of her outstanding contributions to the industrialization of regenerative medical aesthetics, Ms. Li was appointed Chairperson of the Board of Regen Healthcare. She is also actively leading the Company’s strategic planning and execution for a U.S. listing.

Chief Executive Officer, Director - China

EDISON CHEN

Holding dual degrees in Pharmacy and International Finance from Monash University (Australia), he brings over 13 years of experience in cross-border e-commerce and international import–export trade. He specializes in cross-border market strategy, end-to-end supply chain integration, and compliance-driven risk management.

He founded HM, Australia’s largest cross-border e-commerce supply chain platform, and was recognized with the Outstanding Contribution Award at the China Beauty Expo. He has led the full integration of China–Australia cross-border trade value chains, successfully enabling multiple product categories to enter and scale across major overseas markets.

With particularly deep insight into high-barrier sectors such as healthcare and personal care & beauty, his work remains focused on building efficient and resilient commercial pathways that connect China’s manufacturing capabilities with global markets.

Chief Executive Director

KEVIN LOU

Professor Kevin Lou brings over 40 years of cross-disciplinary professional experience, with more than 15 years focused on biotechnology R&D management, higher education, and enterprise training. He has a strong background in industry–academia–research integration, bridging scientific innovation with commercial application.

He has previously served as Chief Executive Officer of Baoneng Biotechnology, Changli Nano Biotechnology, and Shishi Haixing Food Company, as well as Chief Operating Officer and Executive Director of Aberdeen United Limited (Hong Kong). He has also acted as a consultant to the Health Knowledge Promotion Center of Preferred Customer International (Taiwan) and currently serves as an advisor to Zhongke Zhongluan Biotechnology (Guangdong) Co., Ltd. (China).

Professor Lou holds a Doctor of Management from Fudan University (Shanghai) and a PhD in Biotechnology from Da-Yeh University, in addition to a Master’s degree in Pharmacy from Tajen University of Science and Technology and a Master’s degree in Management from the University of St. Thomas (USA). He also holds professional certifications including Cosmetics Safety Assessor and Certified Professional Technologist, and has served as an expert contributor to Taiwan’s Ministry of Science and Technology RAISE Program, leading multiple government-funded research projects.

His R&D achievements include multiple invention patents and registered trademarks in China and Taiwan, covering areas such as functional health foods, eye-care formulations, immune enhancement, and antioxidant technologies.

Chief Scientific Officer

Chief Technology Officer

FARALYNN WONG

Ms. Faralynn brings over 35 years of multinational corporate experience in marketing and senior leadership, with a career spanning key sectors including telecommunications, technology, and financial services. She has held senior management roles with globally recognized companies such as Motorola, Hewlett-Packard, BT, and Pacific Group, where she led key account management, brand strategy, corporate affairs, and Asia-Pacific alliance development initiatives.

Ms. Faralynn currently serves as Chief Marketing Officer (CMO) of RS, where she leads investor relations and IPO strategy. She has successfully translated her extensive telecommunications and commercial operations background into innovative financial services solutions, supporting club members with services including online offshore banking access, virtual card systems, e-wallet solutions, and standby letter of credit (SBLC) applications.

With a strong command of brand governance and corporate compliance, she focuses on helping pre-IPO and high-growth enterprises establish robust governance frameworks and provides strategic guidance for public offerings and capital-raising initiatives. She serves as a key bridge between traditional industries, marketing strategy, and modern capital markets.

Chief Marketing Officer

WONG WAN YUN

Ms. Wong Wan Yun is the Founding Partner and Director of Business Development of EI-Biz Management Pte. Ltd. (卓诚商业管理私人有限公司). She specializes in delivering integrated accounting, taxation, corporate secretarial, and compliance solutions to clients across diverse industries. With over 15 years of professional experience, Ms. Wong has deep expertise in audit, tax advisory, corporate governance, and strategic business consulting.

From 2015 to 2017, Ms. Wong provided freelance accounting services to multiple startups and small-to-medium enterprises. Through this experience, she gained a strong understanding of the market’s growing demand for versatile finance professionals—those capable of managing not only accounting functions, but also tax advisory and corporate secretarial services.

At EI-Biz, Ms. Wong leads the firm’s business expansion and strategic development, leveraging her strong financial insight to advise clients on regulatory compliance, operational optimization, and long-term growth strategies. EI-Biz serves clients across a wide range of sectors, including family offices, food & beverage, construction, wholesale and retail, healthcare, jewelry, and social media marketing.

Chief Financial Officer